Speed and Efficiency in Designing and Building a Monoclonal Antibodies Pilot Plant - A close-up look at Pfizer's biotherapeutics plant under development in Shanbally, Ireland. - BioPharm International

ADVERTISEMENT

Speed and Efficiency in Designing and Building a Monoclonal Antibodies Pilot Plant
A close-up look at Pfizer's biotherapeutics plant under development in Shanbally, Ireland.


BioPharm International
Volume 22, Issue 3

CONCLUSION

Currently, the Shanbally plant construction is more than 60% complete and the commissioning and qualification activity is just starting. Project team members who were formerly involved with the project design phase have transitioned to commissioning activities. Recently hired Shanbally plant colleagues will participate in equipment commissioning activities as part of their education and development program.

Other teams are developing plant manufacturing and quality systems in preparation for plant start up, with engineering batches planned for 2009. There is a detailed operation readiness plan in place and we are currently 30% complete in this area. The laboratories will come online in March 2009, and will be ready to support testing of the initial production batches.

As Shanbally's finishing touches come together and the plant nears completion, the hard work of hundreds of people, inside and outside the company, brings Pfizer another step closer to its objective.

Desmond Fitzgerald is the project leader of the Shanbally project and Ken Bradley is the site leader at the Shanbally plant, both of Pfizer Inc, Shanbally, Ireland, +353 21 500 7947,

REFERENCES

1. Wagenigen University [homepage on the Internet]. Wagenigen, the Netherlands: Innovation in Biopharmaceutical Process Development and Manufacturing; 2006 [cited 2009 Jan]. Available from: http://www.bionovations.org/.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here